Navigation Links
QuantRx Biomedical Settles Suit: Launches New PAD-Based Genomic Diagnostic Products
Date:7/14/2011

PORTLAND, Ore., July 14, 2011 /PRNewswire/ -- QuantRx® Biomedical Corporation (OTCBB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has settled the lawsuit with NURX, its prior Joint Venture partner, with prejudice, and will be focusing its operations to expand its over-the-counter products and laboratory diagnostics to better serve its growing market demands.  The settlement allows NURX to become QN Diagnostics, complete the development of the technology that was the basis of the QND Joint Venture, and provides QuantRx shareholders with 12 million shares of the new entity while voiding 4 million warrants in QuantRx.

The operational changes will facilitate the transition by QuantRx from the Joint Venture-based developmental stage company to an enterprise focused on the marketing and manufacturing of innovative over-the-counter (OTC) healthcare products and expanding its genomic-based diagnostic technology targeting the monitoring of recurring cancers and serious fetal genomic disease and health conditions to the market. The company's OTC pads for daily feminine hygiene and intergluteal pads for the temporary relief of hemorrhoids are being readied for market launch. Of special significance, the company is initiating a clinical study to confirm its innovative, and potentially practice changing, approach to fetal genomic diagnostics using its patented PadKit technology.

"Now that the settlement with our former joint venture partner has been successfully concluded, we will focus our efforts on bringing our products to the market as quickly as possible," said Shalom Hirschman, MD, QuantRx Chairman and CEO. "As we now move to manufacturing and distribution of our unique products, and establish our brand names, we will need to focus our initial efforts on our market-ready products and validating our key research assumptions. We look to our OTC pads to provide our initial revenue base that will allow the company to pursue its creative diagnostic technologies."

The imminent entry into clinical investigations to develop our novel approach to fetal genomic diagnostics is especially exciting," stated Dr. William Fleming, QuantRx's President & Chief Scientific Officer. "The refocusing of our efforts will enable us to rapidly enter the market and build shareholder value back into QuantRx with revenue and exciting new technology."

About QuantRx Biomedical (www.quantrx.com)

QuantRx Biomedical Corporation (OTCBB: QTXB) is focused on the development and commercialization of innovative over-the-counter and genomic products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms leveraging a vast portfolio of intellectual property, QuantRx's mission is to introduce products for use by its medical laboratory and consumers that deliver more accurate, reliable, and cost-effective diagnoses which result in improved patient care and a reduction in overall healthcare costs.

The QuantRx strategy targets significant market opportunities estimated to be in excess of $5 billion worldwide. The Company's technology portfolio, with more than a dozen patents, patents pending and licensed patents, includes: PAD technology for over-the-counter applications, and the diagnosis and treatment of women's health concerns and other medical needs, and significant investments in genome-based diagnostic chips for the laboratory and healthcare professional markets, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment.

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, management's current plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including; general economic conditions, the Company's need for additional funds, the early state of the products the Company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the Company's ability to avoid infringement of the patent rights of others, and the Company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. QuantRx does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

CONTACTS:
Dr. William Fleming
President and CSO
QuantRx Biomedical Corporation
wfleming@quantrx.com

Investor Relations:
Ann Carter
Executive Vice President, Marketing
acarter@quantrx.com


'/>"/>
SOURCE QuantRx Biomedical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research
2. Saladax Biomedical, Inc. Completes $9 Million Debt Financing With GE Capital
3. NCIIA Funds University Biomedical Engineering Teams at BMEidea Awards
4. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
5. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
6. R. Lindholm Named to Crux Biomedical Board
7. FCC Approval of Finite Element Method for Biomedical Transmitters Puts ANSYS Software in the Spotlight
8. Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth
9. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
10. BioMedical Enterprises, Inc. (BME) Introduces the HammerLock™ Shape Memory Device for Hammertoes.
11. Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
Breaking Medicine News(10 mins):